ARIAD Presents New Preclinical Data Showing AP26113 Inhibits Clinically Relevant Mutants of ALK and ROS1

  ARIAD Presents New Preclinical Data Showing AP26113 Inhibits Clinically
  Relevant Mutants of ALK and ROS1

Business Wire

CAMBRIDGE, Mass. & WASHINGTON -- April 10, 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentation of
preclinical data on AP26113, an investigational inhibitor of anaplastic
lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), and c-ros
oncogene 1 (ROS1), at the American Association for Cancer Research (AACR)
Annual Meeting 2013, in Washington. The study, “AP26113 possesses
pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic
ROS1 fusions,” shows that AP26113 inhibits clinically relevant
crizotinib-resistant ALK mutants and oncogenic ROS1 fusions recently
identified in patients with non-small cell lung cancer (NSCLC).

The research conducted by ARIAD scientists was determined using cell lines
harboring crizotinib-resistant mutant forms of ALK and oncogenic ROS1 fusions,
tested in both in vitro studies and mouse-disease models.

“This preclinical research demonstrates that AP26113 inhibits all nine
clinically identified crizotinib-resistant ALK mutations, at plasma
concentrations we know to be clinically achievable,” said Timothy P. Clackson,
Ph.D., president of research and development and chief scientific officer at
ARIAD. “Some of these mutations were also shown to be resistant to additional
ALK inhibitors other than crizotinib. This supports the potential of AP26113
to offer a pan-ALK inhibitor profile.”

AP26113 was also shown to inhibit ROS1 fusions as potently as it inhibits ALK,
to retain activity against the gatekeeper mutation of ROS1, and to
substantially suppress the outgrowth of resistant ROS1 cells in a mutation
assay, all at clinically achievable plasma concentrations. These data suggest
that AP26113 may be able to avoid the emergence of drug-resistant mutants in
NSCLC patients with these oncogenic gene fusions.


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.comor follow ARIAD on
Twitter (@ARIADPharm).

This press release contains “forward-looking statements” including, but not
limited to, updates on preclinical developments for our product candidates.
Forward-looking statements are based on management's expectations and are
subject to certain factors, risks and uncertainties that may cause actual
results, outcome of events, timing and performance to differ materially from
those expressed or implied by such statements. These risks and uncertainties
include, but are not limited to, preclinical data and early-stage clinical
data that may not be replicated in later-stage clinical studies, the costs
associated with our research, development, manufacturing and other activities,
the conduct, timing and results of pre-clinical and clinical studies of our
product candidates, the adequacy of our capital resources and the availability
of additional funding, and other factors detailed in the Company's public
filings with the U.S. Securities and Exchange Commission. The information
contained in this press release is believed to be current as of the date of
original issue. The Company does not intend to update any of the
forward-looking statements after the date of this document to conform these
statements to actual results or to changes in the Company's expectations,
except as required by law.


ARIAD Pharmaceuticals
For Investors
Kendra Adams, 617-503-7028
For Media
Liza Heapes, 617-621-2315
Press spacebar to pause and continue. Press esc to stop.